What is Zacks Research’s Estimate for BDX FY2025 Earnings?

Becton, Dickinson and Company (NYSE:BDX) – Zacks Research lowered their FY2025 earnings estimates for Becton, Dickinson and Company in a report issued on Tuesday, January 21st. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will earn $14.36 per share for the year, down from their previous estimate of $14.39. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.43 per share. Zacks Research also issued estimates for Becton, Dickinson and Company’s Q4 2025 earnings at $4.21 EPS, Q4 2026 earnings at $4.46 EPS, FY2026 earnings at $15.49 EPS and FY2027 earnings at $16.66 EPS.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same period in the prior year, the firm posted $3.42 earnings per share. The firm’s revenue was up 6.9% on a year-over-year basis.

Several other research firms also recently commented on BDX. StockNews.com downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Evercore ISI boosted their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price target for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Moderate Buy” and a consensus target price of $283.50.

Becton, Dickinson and Company Stock Up 1.2 %

Becton, Dickinson and Company stock opened at $240.19 on Wednesday. The company has a market capitalization of $69.66 billion, a P/E ratio of 40.44, a PEG ratio of 1.72 and a beta of 0.39. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $248.42. The stock has a 50-day simple moving average of $227.13 and a 200-day simple moving average of $232.70.

Becton, Dickinson and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th were paid a $1.04 dividend. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 annualized dividend and a dividend yield of 1.73%. The ex-dividend date was Monday, December 9th. Becton, Dickinson and Company’s payout ratio is currently 70.03%.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 2,838 shares of the business’s stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $223.33, for a total value of $633,810.54. Following the completion of the sale, the executive vice president now directly owns 6,141 shares in the company, valued at approximately $1,371,469.53. The trade was a 31.61 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Roland Goette sold 4,483 shares of the stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $221.01, for a total transaction of $990,787.83. Following the sale, the executive vice president now owns 24,345 shares in the company, valued at approximately $5,380,488.45. This trade represents a 15.55 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 9,344 shares of company stock valued at $2,090,716 over the last 90 days. Corporate insiders own 0.36% of the company’s stock.

Institutional Investors Weigh In On Becton, Dickinson and Company

Several institutional investors have recently bought and sold shares of BDX. Livelsberger Financial Advisory acquired a new stake in shares of Becton, Dickinson and Company during the 3rd quarter valued at $26,000. Ashton Thomas Securities LLC acquired a new stake in Becton, Dickinson and Company during the 3rd quarter worth about $33,000. Tompkins Financial Corp boosted its holdings in shares of Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 46 shares during the period. Sound Income Strategies LLC raised its holdings in shares of Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 44 shares during the period. Finally, Kennebec Savings Bank purchased a new position in Becton, Dickinson and Company during the 3rd quarter worth approximately $46,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.